Stapokibart治疗青少年中重度特应性皮炎:多中心随机双盲安慰剂对照III期试验
该III期试验纳入180例青少年中重度特应性皮炎患者,按2:1随机接受stapokibart或安慰剂治疗18周。第18周时,stapokibart组EASI 75和IGA应答率均显著高于安慰剂组,且瘙痒改善更明显,不良事件发生率与安慰剂相似。
要点
- Stapokibart 300mg(负荷600mg)每2或3周皮下注射,治疗青少年中重度AD。
- 第18周EASI 75达73.9% vs 安慰剂43%,IGA应答57.1% vs 25%。
- 不良事件发生率与安慰剂相似(62.5% vs 62%),未报告结膜炎。
核心结论
- Stapokibart在青少年中重度特应性皮炎中显示出高疗效和良好安全性。
研究设计与样本
- 多中心随机双盲安慰剂对照III期试验(NCT06277765),纳入180例青少年中重度AD患者,按2:1随机接受stapokibart 300mg(负荷600mg)或安慰剂治疗18周,体重≥60kg者每2周给药,30至<60kg者每3周给药。
主要发现
- 第18周EASI 75:stapokibart组73.9%(88/119) vs 安慰剂组43%(26/60),差异30.5%(95%CI 15.3-44.3;P<0.001)。
- 第18周IGA应答(0或1分且较基线下降≥2分):stapokibart组57.1%(68/119) vs 安慰剂组25%(15/60),差异31.8%(95%CI 16.6-44.4;P<0.001)。
- 每周平均每日峰值瘙痒NRS评分较基线下降≥4分的患者比例:stapokibart组36.1%(43/119) vs 安慰剂组15%(9/60),差异21.1%(95%CI 7.4-32.4;P=0.004)。
- 不良事件发生率:stapokibart组62.5%(75/120) vs 安慰剂组62%(37/60),未报告结膜炎。
关键数值与推荐
- 共同主要终点为第18周EASI 75和IGA应答(IGA 0或1分且较基线下降≥2分)的患者比例。
- Stapokibart给药方案:300mg(负荷剂量600mg),体重≥60kg者每2周一次,体重30至<60kg者每3周一次,皮下注射。
临床怎么用
- 对于青少年中重度特应性皮炎,可考虑使用stapokibart 300mg(负荷600mg)皮下注射,根据体重选择每2周或每3周给药。
- 治疗18周可显著改善皮损严重度和瘙痒,且安全性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Moderate-to-severe atopic dermatitis (AD) imposes a significant burden on adolescents and their families, leading to a substantial reduction in quality of life. Treatment options remain limited. Stapokibart, a novel humanized monoclonal antibody that targets interleukin-4Rα, has been approved in China for the treatment of adults with moderate-to-severe AD. OBJECTIVES: To evaluate the efficacy and safety of stapokibart in adolescents with moderate-to-severe AD. METHODS: In this randomized double-blind placebo-controlled phase III trial (NCT06277765), eligible patients were randomized (2 : 1) to stapokibart 300 mg (loading dose 600 mg) or placebo for 18 weeks. Patients with a baseline weight ≥ 60 kg received subcutaneous stapokibart or placebo every 2 weeks (Q2W), while those weighing 30 to < 60 kg received treatment every 3 weeks (Q3W). All patients were given moisturizers during the entire study period. Co-primary endpoints were the proportions of patients achieving a ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI 75) and an Investigator's Global Assessment (IGA) score of clear or almost clear (IGA 0 or 1) with ≥ 2-point reduction from baseline (IGA response) at week 18. Safety was also assessed. RESULTS: Of the 180 enrolled patients, 120 received stapokibart (Q2W, n = 54; Q3W, n = 66) and 60 received placebo (Q2W, n = 26; Q3W, n = 34). In total, 178 (98.9%) patients completed the double-blind treatment. At week 18, higher proportions of patients treated with stapokibart than those treated with placebo achieved EASI 75 [73.9% (n = 88/119) vs. 43% (n = 26/60); difference: 30.5% (95% confidence interval 15.3-44.3; P < 0.001)] and an IGA response [57.1% (n = 68/119) vs. 25% (n = 15/60); difference: 31.8% (95% confidence interval 16.6-44.4; P < 0.001)]. The proportion of patients achieving ≥ 4-point reductions in weekly average of daily Peak Pruritus Numerical Rating Scale score was also significantly higher in the stapokibart group than in the placebo group [36.1% (n = 43/119) vs. 15% (n = 9/60); difference: 21.1% (95% confidence interval 7.4-32.4; P = 0.004)]. The incidence of adverse events was similar between the stapokibart (62.5%; n = 75/120) and placebo (62%; n = 37/60) groups. No conjunctivitis was seen. CONCLUSIONS: Stapokibart has a high efficacy and favourable safety in adolescents with moderate-to-severe AD. An author video to accompany this article is available online. Atopic dermatitis is a long-term skin condition. It causes intense itching and painful patches of dry skin. It is more commonly known as eczema. Adolescents with moderate or severe eczema often need long-term treatment to control the symptoms. In China, a drug called ‘stapokibart’ has recently been approved to treat adults with moderate or severe eczema. This study was done in 32 hospitals in China. We included adolescents with moderate or severe eczema. We treated them with stapokibart or placebo (an inactive or ‘dummy’ medication) for 18 weeks. The patients received their treatment via an injection under their skin. Depending on their weight at the start of the study, patients received treatment every 2 or every 3 weeks. After 18 weeks, patients treated with stapokibart were less itchy and had more of an improvement in their skin than those treated with the placebo. Over half of the patients achieved clear (or almost clear) skin. Finally, we found that stapokibart was safe to take. Undesired results from taking the medication (called ‘adverse events’) were mild or moderate. Our results suggest that stapokibart is an effective and safe treatment option for adolescents with moderate or severe eczema.
引用
- Zhou C, Zhao Y, Zhu G, et al. Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial. Br J Dermatol. 2026. PMID: 41697953. doi:10.1093/bjd/ljag052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。